Neuphoria Therapeutics (NEUP) Competitors $12.31 -0.14 (-1.12%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock NEUP vs. RPTX, CRVO, OKYO, SLGL, VNRX, UNCY, HYPD, BYSI, ELYM, and INKTShould you be buying Neuphoria Therapeutics stock or one of its competitors? The main competitors of Neuphoria Therapeutics include Repare Therapeutics (RPTX), CervoMed (CRVO), OKYO Pharma (OKYO), Sol-Gel Technologies (SLGL), VolitionRx (VNRX), Unicycive Therapeutics (UNCY), Hyperion DeFi (HYPD), BeyondSpring (BYSI), Eliem Therapeutics (ELYM), and MiNK Therapeutics (INKT). These companies are all part of the "pharmaceutical products" industry. Neuphoria Therapeutics vs. Its Competitors Repare Therapeutics CervoMed OKYO Pharma Sol-Gel Technologies VolitionRx Unicycive Therapeutics Hyperion DeFi BeyondSpring Eliem Therapeutics MiNK Therapeutics Repare Therapeutics (NASDAQ:RPTX) and Neuphoria Therapeutics (NASDAQ:NEUP) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, media sentiment, risk, dividends and earnings. Do analysts prefer RPTX or NEUP? Repare Therapeutics presently has a consensus target price of $4.50, suggesting a potential upside of 166.27%. Neuphoria Therapeutics has a consensus target price of $28.00, suggesting a potential upside of 127.46%. Given Repare Therapeutics' higher probable upside, equities analysts clearly believe Repare Therapeutics is more favorable than Neuphoria Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Repare Therapeutics 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50Neuphoria Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to RPTX or NEUP? In the previous week, Repare Therapeutics and Repare Therapeutics both had 2 articles in the media. Repare Therapeutics' average media sentiment score of 1.53 beat Neuphoria Therapeutics' score of 0.95 indicating that Repare Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Repare Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Neuphoria Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is RPTX or NEUP more profitable? Neuphoria Therapeutics' return on equity of 0.00% beat Repare Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Repare TherapeuticsN/A -78.25% -66.85% Neuphoria Therapeutics N/A N/A N/A Do institutionals and insiders believe in RPTX or NEUP? 85.1% of Repare Therapeutics shares are held by institutional investors. Comparatively, 15.9% of Neuphoria Therapeutics shares are held by institutional investors. 11.5% of Repare Therapeutics shares are held by insiders. Comparatively, 0.7% of Neuphoria Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has higher valuation and earnings, RPTX or NEUP? Neuphoria Therapeutics has lower revenue, but higher earnings than Repare Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRepare Therapeutics$53.48M1.36-$84.69M-$2.58-0.66Neuphoria Therapeutics$10K2,314.28-$15.49MN/AN/A Which has more volatility & risk, RPTX or NEUP? Repare Therapeutics has a beta of 0.94, meaning that its share price is 6% less volatile than the S&P 500. Comparatively, Neuphoria Therapeutics has a beta of 0.57, meaning that its share price is 43% less volatile than the S&P 500. SummaryRepare Therapeutics beats Neuphoria Therapeutics on 6 of the 11 factors compared between the two stocks. Get Neuphoria Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NEUP and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NEUP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NEUP vs. The Competition Export to ExcelMetricNeuphoria TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$23.14M$3.11B$5.66B$10.37BDividend YieldN/A2.39%5.75%4.64%P/E RatioN/A21.3275.7526.15Price / Sales2,314.28454.84560.95125.53Price / CashN/A45.2537.6061.28Price / Book0.789.7412.416.36Net Income-$15.49M-$52.93M$3.29B$270.97M7 Day Performance21.88%3.87%1.26%0.36%1 Month Performance48.85%7.65%3.84%6.37%1 Year PerformanceN/A20.14%61.01%28.46% Neuphoria Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NEUPNeuphoria Therapeutics2.3584 of 5 stars$12.31-1.1%$28.00+127.5%N/A$23.14M$10K0.00N/AUpcoming EarningsGap UpRPTXRepare Therapeutics3.0685 of 5 stars$1.71-3.1%$4.50+163.2%-50.6%$75.82M$53.48M-0.66180CRVOCervoMed3.7562 of 5 stars$7.79-3.8%$19.29+147.6%-46.0%$74.95M$9.74M-2.984Positive NewsGap UpOKYOOKYO Pharma2.3038 of 5 stars$1.98-4.3%$7.00+253.5%+124.2%$74.47MN/A0.007News CoveragePositive NewsAnalyst ForecastAnalyst RevisionHigh Trading VolumeSLGLSol-Gel Technologies0.6993 of 5 stars$30.50+14.8%N/A+298.6%$74.01M$11.54M-24.8050Gap UpVNRXVolitionRx1.552 of 5 stars$0.68+9.0%$3.50+414.7%-2.7%$73.17M$1.32M-1.8980Positive NewsGap DownHigh Trading VolumeUNCYUnicycive Therapeutics2.4268 of 5 stars$3.96-3.2%$57.00+1,339.4%-11.2%$72.24M$680K-0.969HYPDHyperion DeFi0.4585 of 5 stars$11.28-8.1%$2.00-82.3%-77.3%$69.93M$60K-0.1940News CoverageGap UpBYSIBeyondSpringN/A$1.92+11.6%N/A-18.0%$69.37M$1.75M0.0080Positive NewsGap UpHigh Trading VolumeELYMEliem TherapeuticsN/A$2.31+3.1%N/A-59.1%$68.73MN/A-4.369INKTMiNK Therapeutics3.4657 of 5 stars$15.09-1.7%$37.50+148.5%+79.1%$68.25MN/A-5.2430Gap Up Related Companies and Tools Related Companies RPTX Competitors CRVO Competitors OKYO Competitors SLGL Competitors VNRX Competitors UNCY Competitors HYPD Competitors BYSI Competitors ELYM Competitors INKT Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NEUP) was last updated on 9/26/2025 by MarketBeat.com Staff From Our PartnersWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredWhat The Silver Boom Could Mean For You…AI, electric vehicles, and even global central banks are quietly fueling record demand for silver. This once-o...Goldco Precious Metals | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neuphoria Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neuphoria Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NEUP Stock Alerts